CBER Gene Therapy Office May Be Isolated In FDA Reorganization Plan

FDA's proposed transfer of therapeutic biologic reviews to the drug center could negatively affect the newly created CBER Office of Cellular, Tissue & Gene Therapies, Acting Director Phillip Noguchi, MD, said